Last reviewed · How we verify
Motens (LACIDIPINE)
Lacidipine works by blocking calcium channels in the blood vessels, which helps to lower blood pressure.
Lacidipine, also known as Moten, is a small molecule lacidipine drug that targets Cytochrome P450 3A4. It is a calcium channel blocker used to treat hypertension. The commercial status of lacidipine is unclear, and it is not FDA-approved. Lacidipine has a bioavailability of 18%. Further information on its half-life, generic manufacturers, and patent status is not available.
At a glance
| Generic name | LACIDIPINE |
|---|---|
| Drug class | lacidipine |
| Target | Adenosine receptor A3, Cytochrome P450 2C19, Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Imagine your blood vessels are like roads with traffic flowing through them. Calcium channels are like on-ramps that let more traffic in, making the road more congested. By blocking these on-ramps, lacidipine reduces the amount of calcium flowing into the blood vessels, which helps to relax the blood vessel walls and improve blood flow.
Approved indications
Common side effects
- Procalcitonin abnormal
- Drug interaction
- Encephalomalacia
- PO2 decreased
- PCO2 decreased
- International normalised ratio increased
- Lymphocyte count increased
- Melaena
- Acquired macroglossia
- Device related sepsis
- Scrotal oedema
- Procedural haemorrhage
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients (PHASE4)
- IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer
- Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers (PHASE1)
- Effect of Caldine® on Renal Function in Balanced Hypertension
- A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients (PHASE4)
- Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension
- Efficacy and Safety of Lacidipine in Chronic Stable Angina (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motens CI brief — competitive landscape report
- Motens updates RSS · CI watch RSS